Recent news on Phoslo

Fresenius Medical Care Reports Outstanding Start for 2007 and ...  -  May 2, 2007
Genetic Engineering News (press release),Dialysis Product revenue increased by 14% to $153 million led by strong sales of our 2008K hemodialysis machines and the phosphate binding drug PhosLo.

Nabi to sell drug to Irish pharmaceutical firm  -  Apr 20, 2007
Charlotte Business Journal,The company has already sold off one other marketed product, PhosLo, as well as another product in development, to Fresenius Medical Care for up to $150

Nabi Biopharmaceuticals Announces Fourth Quarter and Full-Year ...  -  Apr 3, 2007
Drug Newswire (press release),Revenues for both years excluded sales of PhosLo(R) (calcium acetate) which are included in discontinued operations. Revenues for the fourth quarter of 2006

Nabi Biopharmaceuticals Announces Agreement to Sell Aloprim  -  Apr 20, 2007
PharmaLive.com (press release),...as well as for the continuing milestone-related clinical development obligations following the sale of PhosLo(R) (calcium acetate).

American Kidney Fund launches Part D grant program  -  Apr 3, 2007
Renal Business Today,The program covers bone disease medications, including Fosrenol, Hecterol, Phoslo, Renagel, Sensipar and Zemplar. Burton added that the AKF hopes to add

American Kidney Fund Launches Medicare Part D Grant Program for ...  -  Apr 3, 2007
PR Web (press release),This program covers common bone disease medications, including Fosrenol®, Hectorol®, Phoslo®, Renagel®, Sensipar® and Zemplar®.

Nabi Biopharmaceuticals Announces Fourth Quarter and Full-Year ...  -  Mar 12, 2007
PR Newswire (press release),Revenues for both years excluded sales of PhosLo(R) (calcium acetate) which are included in discontinued operations. Revenues for the fourth quarter of 2006

Nephrologists Report Practice Pattern Shifts in the Management of ...  -  Feb 1, 2007
PharmaLive.com (press release),In the phosphate binder market, nephrologists report continued shifts away from calcium-based agents (such as Fresenius Medical Care's PhosLo) to non-

New Nabi chief sees plenty of promise  -  Feb 17, 2007
Palm Beach Post,Wasserman believes Nabi's cash position - $130'million in November after the sale of its drug, PhosLo, to German drug maker Fresenius AG - gives Hudson some

Nabi CEO resigns, interim named  -  Feb 16, 2007
South Florida Business Journal,In October, it sold off its PhosLo drug, which treats high phosphate levels in people with kidney failure, for $65 million. It is now developing NicVax for

Recap of South Florida's best, worst in '06  -  Dec 31, 2006
Miami Herald,Earlier this month, Nabi signed a contract to sell its top producing drug, PhosLo, for $150 million to give it much-needed cash for other projects.

Nabi survives year of tumult, but future still cloudy  -  Dec 2, 2006
Palm Beach Post,And its PhosLo deal with Fresenius AG might bring the German drugmaker back for more. Baxter Healthcare Corp. in Deerfield, Ill., might be an acquirer of

Third Point Urges Nabi Directors to Expand Bank of America's ...  Sep 14, 2006
Healthcare Conference Mr. McLain snuck in a slide and commentary during his presentation showing that the Company now expects EU approval for PhosLo in the ... -Yahoo! News

Nabi Biopharmaceuticals Acquires Exclusive Rights to Novel Plasma ...  Aug 29, 2006
The company has three products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) (allopurinol ... -International News Service

Nabi Biopharmaceuticals Acquires Exclusive Rights to Novel Plasma ...  Aug 29, 2006
The company has three products on the market today: PhosLo® (calcium acetate), Nabi-HB® [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) (allopurinol ... -Yahoo! News

FMC unveils positive results for PhosLo renal disease treatment  -  12 Dec 2006
Forbes,FRANKFURT (AFX) - Fresenius Medical Care AG & Co KGaA has announced positive results from a study into its PhosLo treatment for renal disease.

Nabi Finds Option Errors  -  12 Dec 2006
TheStreet.comNabi had been accounting for its PhosLo business as a discontinued operation since its Aug. 7 agreement to sell it to Fresenius Medical Care.

Q3 loss grows at Nabi  -  12 Dec 2006
Bizjournals.com,Tuesday, Nabi closed the sale of its PhosLo treatment for high phosphate levels to Fresenius Medical Care for up to $150 million in up-front cash,

Finding Presented at American Society of Nephrology Annual Meeting  -  12 Dec 2006
Oxfordshire Bioscience Network (press release),Approximately 27 percent of patients in the calcium group opted to use calcium carbonate rather than PhosLo. Patients were treated according to the usual

(PRN) - The Steak n Shake Company Reports Fiscal Fourth Quarter ...  -  12 Dec 2006
Bolsamania.com,...(PRN) - Nabi Biopharmaceuticals Closes Sale of PhosLo(R) to Fresenius Medical Care ... [+]. (PRN) - PHC, Inc. Announces Financial Results for the First

Fresenius Medical Care Announces Positive Results from PhosLo CARE ...  -  Nov 22, 2006
PipelineReview.com (press release),KGaA today announced positive results from the PhosLo (calcium acetate) CARE-2 (Calcium Acetate Renagel Evaluation) study. The study demonstrated that when

Fresenius Medical Care Announces Positive Results from PhosLo CARE ...  -  Nov 21, 2006
PharmaLive.com (press release),The data refute the hypothesis that the calcium in PhosLo contributes to cardiovascular calcification. The findings were presented by Dr. Wajeh Qunibi,

Nabi Biopharmaceuticals Closes Sale of PhosLo to Fresenius Medical ...  -  Nov 15, 2006
PharmaLive.com (press release),Additionally, a number of Nabi Biopharmaceuticals' sales and marketing staff will move with PhosLo to Fresenius' team to continue to promote and market the

Nabi Closes PhosLo Sale With Fresenius  -  Nov 15, 2006
Houston Chronicle,NEW YORK — Nabi Pharmaceuticals closed the $65 million cash sale of its PhosLo products to a subsidiary of Germany-based Fresenius Medical Care.

Market Report -- In Play (FMS)  -  Nov 21, 2006
MSN MoneyFresenius Medical announces positive results from PhosLo CARE-2 study Co announces positive results from the PhosLo CARE-2 study.

Nabi, hedge fundreach deal on directors, chairman  -  Nov 13, 2006
Palm Beach Post,Last month, the company sold its largest revenue generator, PhosLo, to a US subsidiary of German drug maker Fresenius AG for up to $150 million in cash and

Fresenius Medical Care Completes the Acquisition of the Phosphate ...  -  Nov 15, 2006
PharmaLive.com (press release),KGaA (NYSE:FMS)(FWB:FME) today announced that it has completed the acquisition of the worldwide phosphate binder business (PhosLo) from Nabi

Nabi Biopharmaceuticals Announces Satisfactory Completion of ...  -  Nov 14, 2006
PR Newswire (press release),The assets, liabilities, revenue and expenses related to PhosLo are reflected in discontinued operations for all periods presented as a result of the

Nabi survives year of tumult, but future still cloudy  -  Dec 2, 2006
Palm Beach Post,And its PhosLo deal with Fresenius AG might bring the German drugmaker back for more. Baxter Healthcare Corp. in Deerfield, Ill., might be an acquirer of

Nabi Biopharmaceuticals and Third Point Reach Agreement  -  Nov 13, 2006
Drug Newswire (press release),The company has three products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM)

Nabi Biopharmaceuticals and Third Point Reach Agreement  -  Nov 13, 2006
Yahoo! News (press release)The company has three products on the market today: PhosLo® (calcium acetate), Nabi-HB® [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) (allopurinol

invivodata and Medidata Solutions Announce Integration of DiaryPRO ...  29 Aug 2006
The company has three products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R) (Hepatitis B Immune Globulin (Human)), and Aloprim(TM) (allopurinol ... -Business Wire

Nabi Biopharmaceuticals Reports Second Quarter 2006 Results  Jul 26, 2006
...quarter of 2005. The increase was driven by improved pricing and strong patient demand for PhosLo® (calcium acetate). Net loss ... -Yahoo! News

Prometic Life Sciences Signs Strategic License Agreement With Nabi ...  Aug 22, 2006
The company has three products on the market today: PhosLo® (calcium acetate), Nabi-HB® [Hepatitis B Immune Globulin (Human)], and Aloprim™ (allopurinol ... -PipelineReview.com

Nabi Biopharmaceuticals Reports Second Quarter 2006 Results  Jul 26, 2006
The increase was driven by improved pricing and strong patient demand for PhosLo(R) (calcium acetate). ... study on control of operations. superiority of PhosLo. ... -PharmaLive.com

Nabi sees smaller Q2 loss  Jul 28, 2006
...million. For its smaller loss, Nabi credited improved pricing and strong patient demand for its PhosLo calcium acetate. Accentuating ... -San Antonio Business Journal

Third Point Demands that Nabi Directors Immediately Empower Bank ...  Aug 17, 2006
...by Mr. McLain to shareholders (dating back to a projected approval in the 4th quarter of 2005), Nabi yet again failed to secure EU approval for PhosLo in the ... -Drug Newswire



Nabi Biopharmaceuticals Announces First Quarter 2006 Financial ...  Apr 26, 2006
...- Gains in Product Revenues and Margins Led by PhosLo - - Significant Progress Made in Advancing Key Strategic Objectives - BOCA RATON, Fla., April 26 ... - PR Newswire

Nabi Biopharmaceuticals Announces First Quarter 2006 Financial ...  Apr 26, 2006
...announced gains in total revenues and the gross margin earned on sales in the first quarter of 2006 primarily reflecting strong results for PhosLo(R) (calcium ... - PR Newswire

Genzyme says petition against Renagel ‘inaccurate’  May 12, 2006
...was not available for immediate contact. Nabi sells PhosLo, a rival drug to Genzyme’s Renagel. According to the petition, Nolan ... - Renal Business Today

New anti-smoking drug may rival Nabi vaccine  May 11, 2006
Nolan noted that he has done consulting work for Boca Raton-based Nabi, which sells PhosLo, Renagel's biggest competitor. If the ... - Palm Beach Post

Nabi strikes plasma deal as losses rise  Apr 26, 2006
McLain pointed to a jump in the sale of PhosLo, a medication that reduces dangerously high phosphate levels in the blood, as evidence that the drug is on track ... - Palm Beach Post

Doctor calls for withdrawal of Renagel  May 11, 2006
In the petition, Nolan used data provided by Nabi Pharmaceuticals, which sells the rival drug PhosLo. Nolan has consulted with Nabi in the past. ... - Renal Business Today

Nabi Biopharmaceuticals Announces Results of 2006 Annual Meeting ...  May 12, 2006
The company has three products on the market today: PhosLo® (calcium acetate), Nabi-HB® [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) (allopurinol ... - Yahoo! News

Nabi logs larger loss in Q1  Apr 27, 2006
...longer sells. The company credited much of its most recent revenue gain to PhosLo, a drug for patients with kidney disease. Nabi ... - Bizjournals.com





Nabi Biopharmaceuticals Acquires Exclusive North American ...  Apr 3, 2006
The company has three products on the market today: PhosLo® (calcium acetate), Nabi-HB® [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) (allopurinol ... - Yahoo! News

Nabi starts over with StaphVAX  Mar 21, 2006
Without it, Nabi would have to fall back on drugs that don't generate enough revenue to sustain the company, including PhosLo, a medication that reduces ... - Palm Beach Post

Florida-Based Nabi Biopharmaceuticals Looks for a Cure in Nicotine ...  Mar 13, 2006
...a net loss of $75.6 million - nearly 60 percent of the year's losses.Webb said the poor showing was due in large part to Nabi's low sales of PhosLo, a kidney ... - International News Service

Braintree Laboratories, Inc. In-Licenses Global Rights to Oncology ...  Mar 9, 2006
In 1990 Braintree received approval for PhosLo®(1) (Calcium Acetate) which was a dietary phosphate binder for end stage renal disease patients. ... - Yahoo! News



Nabi posts $75.6 million loss  Feb 23, 2006
The company identified errors calculated in the Medicaid rebate amount for its PhosLo drug for the first three quarters of 2005 that it translated to a $3.9 ... - South Florida Business Journal,

Nabi Biopharmaceuticals to Present at the Lehman Brothers Ninth ...  Mar 3, 2006
The company has three products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) (allopurinol ... - PR Newswire,

Nabi Biopharmaceuticals to Hold Conference Call to Provide Summary ...  Feb 6, 2006
We have three products on the market today: PhosLo® (calcium acetate), Nabi-HB® [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) [Allopurinol sodium ... - Yahoo! News

Nabi Biopharmaceuticals to Hold Conference Call to Provide Summary ...  Feb 6, 2006
We have three products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) [Allopurinol sodium ... - PR Newswire

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional